Dynamic Maternal Phenotyping in Pregnancy: A Scientific Review

Abstract

Dynamic maternal phenotyping in pregnancy refers to the longitudinal and integrative characterization of pregnant individuals using advanced clinical, laboratory, and omics-based assessments. This evolving approach enables precise identification of maternal profiles, predicting risk trajectories, and informing individualized care. Recent evidence underscores the value of dynamic phenotyping in optimizing pregnancy outcomes through tailored interventions, risk stratification, and improved understanding of pregnancy-related pathophysiology. This review synthesizes current epidemiological data, mechanistic insights, clinical features, and recent advances, with a focus on practical implications for obstetric care.

Introduction

Pregnancy is a complex physiological state marked by dynamic changes in maternal biology. Traditional risk assessments often rely on static variables, potentially overlooking the temporal evolution of risk profiles. Dynamic maternal phenotyping, leveraging serial clinical, biomarker, and multi-omics data, offers a paradigm shift in obstetric risk assessment and management. By capturing the trajectory of maternal adaptation, this approach provides a foundation for precision medicine in obstetrics. Clinicians must stay abreast of these advances to enhance maternal-fetal outcomes through evidence-based, individualized care.

Epidemiology / Disease Burden

Globally, adverse pregnancy outcomes such as preeclampsia, preterm birth, and gestational diabetes mellitus (GDM) contribute substantially to maternal and perinatal morbidity and mortality. Approximately 15% of pregnancies are affected by hypertensive disorders, while GDM impacts up to 10%. The heterogeneity in maternal risk, influenced by genetic, environmental, and socio-demographic factors, underscores the need for dynamic phenotyping. Epidemiological studies reveal that static risk assessment tools fail to fully capture the temporal and multifactorial nature of pregnancy complications, leading to suboptimal prediction and prevention strategies.

Pathophysiology

Dynamic maternal phenotyping seeks to delineate the pathophysiological transitions that occur during pregnancy. These include cardiovascular remodeling, immunological adaptation, and metabolic shifts, all of which evolve over gestation. For example, impaired placentation and maladaptive maternal cardiovascular responses underlie preeclampsia, while dysregulated glucose metabolism characterizes GDM. Recent omics-based studies have identified dynamic biomarkers—proteomic, metabolomic, and transcriptomic signatures—that precede clinical onset of complications, offering mechanistic insights into disease progression and maternal adaptation.

Risk Factors

Identifying dynamic risk factors is central to personalized obstetric care. Traditional risk factors—maternal age, obesity, preexisting hypertension, and diabetes—interact with dynamic variables such as evolving inflammatory markers, placental growth factor levels, and gestational weight gain. Longitudinal tracking enables early detection of deviation from physiological adaptation, providing actionable windows for intervention. Socioeconomic status and access to healthcare further modulate risk profiles, highlighting the need for context-specific phenotyping models.

Clinical Features

Dynamic maternal phenotyping informs the recognition of evolving clinical features. For instance, increasing blood pressure, new-onset proteinuria, or rising liver enzymes may signify progression to preeclampsia. Serial monitoring of glycemic control delineates the trajectory toward GDM. Subtle changes in fetal growth parameters, maternal symptoms, or laboratory markers, when interpreted dynamically, enhance early diagnosis and optimize surveillance strategies. Distinguishing physiological from pathological changes requires integration of serial data within the clinical context.

Diagnosis

Diagnosis using dynamic phenotyping incorporates serial clinical examination, laboratory trends, and advanced imaging. Technologies such as continuous glucose monitoring, ambulatory blood pressure tracking, and repeated Doppler ultrasonography facilitate real-time assessment. Omics platforms enable non-invasive identification of predictive biomarkers in maternal plasma. Machine learning models, trained on longitudinal datasets, are emerging as powerful tools to synthesize multi-dimensional data, improving the accuracy and timeliness of diagnosis compared to conventional static algorithms.

Treatment & Management

Management strategies informed by dynamic phenotyping emphasize timely, individualized interventions. For women at high dynamic risk of preeclampsia, low-dose aspirin prophylaxis initiated before 16 weeks may be beneficial. Serial risk assessment informs intensity of monitoring and timing of therapeutic escalation. Personalized glycemic targets and pharmacological regimens in GDM, guided by continuous glucose trends, improve maternal-fetal outcomes. Dynamic phenotyping also informs decisions regarding delivery timing in high-risk pregnancies, balancing maternal and neonatal risks.

Recent Advances / Emerging Therapies

Recent advances include integration of multi-omics data, wearable biosensors, and artificial intelligence-driven predictive analytics. Ongoing studies are evaluating circulating placental microRNAs, cell-free fetal DNA, and novel metabolic markers for early detection of complications. Telemedicine platforms facilitate remote monitoring, increasing access and continuity of care. Emerging therapeutics targeting specific pathophysiological pathways—such as angiogenic modulators for preeclampsia—are under investigation, guided by dynamic risk stratification.

Guideline Recommendations

Professional societies increasingly advocate for individualized risk assessment throughout pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and International Federation of Gynecology and Obstetrics (FIGO) recommend early and repeated evaluation of maternal risk factors, with consideration of biomarker-based screening for high-risk populations. Guidelines emphasize the integration of clinical, laboratory, and imaging data, and encourage research into dynamic phenotyping models to refine prediction and prevention strategies.

Conclusion

Dynamic maternal phenotyping marks a significant advancement in obstetric care, offering a mechanism-based, personalized approach to risk assessment and management. By integrating serial clinical and omics data, clinicians can better predict, prevent, and treat pregnancy complications. Ongoing research and implementation of dynamic phenotyping into clinical practice hold promise for improving maternal and perinatal outcomes worldwide. Continuous education and adoption of emerging technologies are essential to fully realize the benefits of this transformative approach in maternal-fetal medicine.